Tempest Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 0.4955 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 8.20M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Details
| Name | Tempest Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 4 |
| Founded | 2011 |
| Ceo | Matthew Angel |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US87978U2078 |
| Cusip | 87978U207 |
| Cik | 1544227 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Dr. Andrew Fang Ph.D. | Head of Business Development |
Contact
| Address | 2000 Sierra Point Parkway, Suite 400, Brisbane, California 94005, United States |
| Phone | 415 798 8589 |
| Website | https://www.tempesttx.com |